



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent
Licensee of the Blue Cross and Blue Shield Association

Pharmacy Medical Policy RSV Immunoprophylaxis

Table of Contents

- [Policy: Commercial](#)
- [Policy History](#)
- [References](#)
- [Coding Information](#)
- [Information Pertaining to All Policies](#)
- [Forms](#)

Policy Number: 422

Related Policies

None

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Note: All requests for outpatient retail pharmacy for indications listed and not listed on the medical policy guidelines may be submitted to BCBSMA Clinical Pharmacy Operations by completing the Prior Authorization Form on the last page of this document. Physicians may also call BCBSMA Pharmacy Operations department at (800)366-7778 to request a prior authorization/formulary exception verbally. Patients must have pharmacy benefits under their subscriber certificates.

BCBSMA covers Palivizumab (Synagis™) in accordance with the American Academy of Pediatrics Guidelines, injections are given once a month during the RSV season. The 2014 American Academy of Pediatrics guidelines noted that the first dose should be administered at the beginning of November and the last dose should be administered at the beginning of March, which provides protection into April. Unless otherwise specified below, one course of treatment will be defined as five monthly doses typically given from November through March. Qualifying infants born during the RSV season may require fewer doses.

First Course of Treatment

Prematurity: We cover one course of prophylaxis with palivizumab for infants and children who were born prematurely, as follows:²

- Infants born at 28 weeks 6 days of gestation or earlier may benefit if they are less than 12 months of age at start of the RSV season²

Reduced lung reserve: We cover prophylaxis with palivizumab for infants who are 12 months or younger at the start of the RSV season and develop chronic lung disease (CLD) of prematurity defined as:

- Gestational age < 32 weeks, 0 days
- Requirement for > 21% oxygen for at least first 28 days after birth

Anatomic pulmonary abnormalities/Neuromuscular diseases:² We cover prophylaxis with palivizumab for children with neuromuscular diseases that affect respiratory mechanics if they are 12 months or younger at the start of the RSV season.²

Congenital heart defects:² We cover prophylaxis with palivizumab for infants with hemodynamically significant congenital heart defects in the following circumstances if they are 12 months or younger at the start of the RSV season:

- Infants with acyanotic heart disease who are receiving medication to control congestive heart failure and will require cardiac surgical procedures
- Infants with moderate to severe pulmonary hypertension
- Infants with cyanotic heart disease at the recommendation of a pediatric cardiologist

Surgical procedures: For infants/children who are receiving prophylaxis and who continue to require prophylaxis after cardiopulmonary bypass, a postoperative dose of palivizumab (15 mg/kg) should be considered after surgery or at the conclusion of extracorporeal membrane oxygenation for infants and children younger than 24 months.

Cardiac transplantation: We cover palivizumab prophylaxis for infants/children younger than 2 years who undergo cardiac transplantation during the RSV season.

Immunocompromised children: We cover prophylaxis with palivizumab for infants/children younger than 24 months of age who are profoundly immunocompromised during the RSV season.

Cystic Fibrosis: We cover prophylaxis with palivizumab for infants with cystic fibrosis with clinical evidence of CLD and/or nutritional compromise in the first year of life.

Second Course of Treatment

- Infants/children younger than 24 months of age who meet the chronic lung disease of prematurity definition above may benefit from RSV immunoprophylaxis for a second RSV season if they continue to require medical support (chronic corticosteroid therapy, diuretic therapy or supplemental oxygen) during the six month period before the start of the second RSV season.
- Infants/children younger than 24 months of age who are profoundly immunocompromised during the RSV season may benefit from a second season of prophylaxis.
- Infants/children younger than 24 months of age with cystic fibrosis may benefit from palivizumab prophylaxis for a second RSV season who have manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or chest computed tomography that persist when stable) or weight for length less than the 10th percentile.

We do not cover experimental uses not approved by the FDA, because there is not enough published scientific information about health outcomes for other uses. For example, we do not cover palivizumab for adults.

We do not cover this drug for infants/children receiving palivizumab prophylaxis who experience a breakthrough RSV hospitalization. Monthly prophylaxis should be discontinued because of the extremely low likelihood of a second RSV hospitalization in the same season.

We do not cover this drug for infants born at > 29 weeks 0 days gestation, except for those indicated above.

The following groups of infants are not at increased risk of RSV and generally should not receive immunoprophylaxis:

- Infants and children with hemodynamically insignificant heart disease (e.g., secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus)

- Infants with lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure
- Infants with mild cardiomyopathy who are not receiving medical therapy for the condition

We do not cover this drug for infants with Down syndrome unless qualifying heart disease, CLD, airway clearance issues, or prematurity (< 29 weeks, 0 days' gestation) is present.

We do not cover this drug for infants/children with cystic fibrosis unless above criteria are met.

We do not cover this drug for prophylaxis for primary asthma prevention or to reduce subsequent episodes of wheezing.

Individual Consideration

All our medical policies are written for the majority of people with a given condition. Each policy is based on medical science. For many of our medical policies, each individual's unique clinical circumstances may be considered in light of current scientific literature. Physicians may send relevant clinical information for individual patients for consideration to:

Blue Cross Blue Shield of Massachusetts
 Pharmacy Operations Department
 25 Technology Place
 Hingham, MA 02043
 Tel: 1-800-366-7778
 Fax: 1-800-583-6289

Prior Authorization Information

Outpatient

For services described in this policy, see below for products where prior authorization **IS REQUIRED** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is required .
Commercial PPO	Prior authorization is required .

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member. Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

PALIVIZUMAB (SYNAGIS™) when administered in the office:

Option #1

- The pediatrician will request the dose required from the contracted Specialty Retail Pharmacy or HIT provider below:

Vendor:	Contact Information:	
AcariaHealth.(Specialty Only)	Telephone:	1-844-796-2447
	Fax:	1-866-892-3223
	Website:	www.acariahealth.com

Accredo (Specialty Only)	Telephone:	1-877-482-5927, Option 3
	Fax:	1-866-489-1907
	Website:	www.accredo.com
CVS Specialty (Caremark, Inc.) (Specialty and HIT*)	Telephone:	1-800-237-2767
	Fax:	1-800-323-2445
	Website:	www.caremark.com

*Any Participating Home Infusion Provider can submit and bill under their Home Infusion agreement for Synagis

- The Specialty Retail Pharmacy or HIT provider will ship the Synagis™ directly to the physician's office.
- The Specialty Retail Pharmacy or HIT provider will bill BCBSMA directly for the reimbursement of the drug sent to the physician according to the appropriate benefit.
- Coverage for the drug will be applied to the members Specialty Retail Pharmacy or HIT benefit. (The pediatrician has no out-of-pocket expense for the drug up front. Applicable co-pays/coinsurance will apply.)

Note: The above arrangement is **only** for the reimbursement for Synagis™ and no other immunizations.

Option #2

- Use CPT code 90378 to report respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each.
- If the physician has purchased Synagis™ from his/her regular drug vendor, bill for the cost of the drug using CPT code 90378.
- The physician may bill for the administration of Synagis™ using CPT code 96372. **Home Infusion Therapy Providers:** Use CPT code 90378.

The above medical necessity criteria **MUST** be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:

CPT Codes

CPT codes:	Code Description
90378	Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each

The following ICD Diagnosis Codes are considered medically necessary when submitted with the CPT code above if medical necessity criteria are met:

ICD-10 Diagnosis Codes

ICD-10-CM Diagnosis codes:	Code Description
B97.4	Respiratory syncytial virus as the cause of diseases classified elsewhere
J12.1	Respiratory syncytial virus pneumonia
J20.5	Acute bronchitis due to respiratory syncytial virus
J21.0	Acute bronchiolitis due to respiratory syncytial virus
Z23	Encounter for immunization
Z29.11	Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSV)

Policy History

Date	Action
10/2020	References updated.
4/2020	Removed BriovaRx from the Provider section.
10/2019	References updated.

9/2018	Added Accredo and BriovaRx to the Provider section.
7/2018	Clarified coding information.
11/2017	Added the State Standard PA form to the policy.
10/2017	Updated to change Walgreens Specialty Name.
6/2017	Updated address for Pharmacy Operations.
10/2016	Clarified second course of therapy Criteria.
10/2015	Updated to add Walgreens as a Specialty Rx Vendor.
8/2014	Update to include 2014 AAP practice guidelines.
7/2014	Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015.
9/2013	Updated to include 2013-14 vendor information.
9/2012	Updated: 9/2012 to update 2012 AAP guidelines and update HIT and Specialty Retail Pharmacy Network contact information.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
9/2011	Updated to include update HIT and Specialty Retail Pharmacy Network contact information.
5/2011	Reviewed - Medical Policy Group - Pediatrics and Endocrinology. No changes to policy statements.
10/2010	Updated to include preferred vendor information for 2010-2011 RSV season.
5/2010	Reviewed - Medical Policy Group - Pediatrics and Endocrinology. No changes to policy statements.
10/2009	Updated to include new 2009 AAP practice guidelines and UM requirements.
5/2009	Reviewed - Medical Policy Group - Pediatrics and Endocrinology. No changes to policy statements.
5/2008	Reviewed - Medical Policy Group - Pediatrics and Endocrinology. No changes to policy statements.
9/2007	Updated to include additional references for 2006 American Academy of Pediatric Guidelines.
5/2007	Reviewed - Medical Policy Group - Pediatrics and Endocrinology. No changes to policy statements.
2/1997	New policy, issued 2/1997, describing covered and non-covered indications.

References

1. American Academy of Pediatrics. AAP publications reaffirmed. <https://pediatrics.aappublications.org/content/144/2/e20191767>. Accessed June 20, 2020
2. Munoz FM RS, Meissner HC. RSV Recommendations Unchanged after Review of New Data. AAP News 2017; <http://www.aappublications.org/news/2017/10/19/RSV101917>. Accessed June 15, 2020
3. Brady MT, Byington CL, Davies HD, et al. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics*. Aug 2014; 134(2): e620-38. PMID 25070304
4. Rose EB, Wheatley A, Langley G, et al. Respiratory Syncytial Virus Seasonality - United States, 2014-2017. *MMWR Morb Mortal Wkly Rep*. Jan 19 2018; 67(2): 71-76. PMID 29346336
5. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. *N Engl J Med*. Feb 05 2009; 360(6): 588-98. PMID 19196675
6. Food and Drug Administration. Label: Synagis (Palivizumab) for Intramuscular Administration. 2017; <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e35c4c8-bf56-458f-a73c-8f5733829788>. Accessed June 15, 2020
7. Falloon J, Ji F, Curtis C, et al. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. *Vaccine*. May 27 2016; 34(25): 2847-54. PMID 27102821
8. Glenn GM, Fries LF, Thomas DN, et al. A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. *J Infect Dis*. Feb 01 2016; 213(3): 411-22. PMID 26259809

9. Homaira N, Rawlinson W, Snelling TL, et al. Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective. *Int J Pediatr.* 2014; 2014: 571609. PMID 25548575
10. Andabaka T, Nickerson JW, Rojas-Reyes MX, et al. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. *Cochrane Database Syst Rev.* Apr 30 2013; (4): CD006602. PMID 23633336
11. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. *J Pediatr.* Oct 2003; 143(4): 532-40. PMID 14571236
12. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMPact-RSV Study Group. *Pediatrics.* Sep 1998; 102(3 Pt 1): 531-7. PMID 9738173
13. Subramanian KN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. *Pediatr Infect Dis J.* Feb 1998; 17(2): 110-5. PMID 9493805
14. Tavsu I, Gursoy T, Dirman S, et al. Palivizumab prophylaxis: does it have any influence on the growth and development of the infants?. *Am J Perinatol.* Sep 2014; 31(8): 667-72. PMID 24022378
15. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. *N Engl J Med.* May 09 2013; 368(19): 1791-9. PMID 23656644
16. Farber HJ, Buckwold FJ, Lachman B, et al. Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants. *Pediatrics.* Aug 2016; 138(2). PMID 27432850
17. Ozyurt A, Narin N, Baykan A, et al. Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study. *Pediatr Pulmonol.* Oct 2015; 50(10): 1025-32. PMID 25156973
18. Cohen SA, Zanni R, Cohen A, et al. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry. *Pediatr Cardiol.* Mar 2008; 29(2): 382-7. PMID 17926087
19. Sanchez-Solis M, Gartner S, Bosch-Gimenez V, et al. Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis. *Allergol Immunopathol (Madr).* May-Jun 2015; 43(3): 298-303. PMID 24231153
20. Robinson KA, Odelola OA, Saldanha I, et al. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. *Cochrane Database Syst Rev.* Feb 17 2010; (2): CD007743. PMID 20166098
21. Robinson KA, Odelola OA, Saldanha IJ, et al. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. *Cochrane Database Syst Rev.* Feb 15 2012; (2): CD007743. PMID 22336832
22. Robinson KA, Odelola OA, Saldanha IJ. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. *Cochrane Database Syst Rev.* May 22 2014; (5): CD007743. PMID 24851825
23. Robinson KA, Odelola OA, Saldanha IJ. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. *Cochrane Database Syst Rev.* Jul 20 2016; 7: CD007743. PMID 27439110
24. Groves HE, Jenkins L, Macfarlane M, et al. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland. *Pediatr Pulmonol.* Apr 2016; 51(4): 379-85. PMID 26808981
25. Lanari M, Vandini S, Capretti MG, et al. Respiratory syncytial virus infections in infants affected by primary immunodeficiency. *J Immunol Res.* 2014; 2014: 850831. PMID 25089282
26. Gaboli M, de la Cruz OA, de Agüero MI, et al. Use of palivizumab in infants and young children with severe respiratory disease: a Delphi study. *Pediatr Pulmonol.* May 2014; 49(5): 490-502. PMID 23775884
27. Manzoni P, Leonessa M, Farina D, et al. Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting. *Pediatr Transplant.* Jun 2007; 11(4): 456-7. PMID 17493231
28. Yi H, Lancot KL, Bont L, et al. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study. *Pediatrics.* Jun 2014; 133(6): 1031-7. PMID 24799541

29. Brady MT, Byington CL, Davies HD, et al. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics*. Aug 2014; 134(2): 415-20. PMID 25070315
30. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. *Pediatrics*. Nov 2014; 134(5): e1474-502. PMID 25349312

Massachusetts Standard Form for Synagis Prior Authorization Requests (eForm)

If NOT logged into Provider Central use this link:

[Massachusetts Standard Form for Synagis Prior Authorization Requests eForm](#)

(Also found on Provider Central at **Forms > Authorization – Pharmacy**)

If logged into Provider Central use this link:

[Provider Central Link to Pharmacy Forms](#)

(Also found on Provider Central by clicking **Forms** on the top of the page, then choose **Authorization – Pharmacy**)

Tips for using this eForm:

- Fill out completely and submit it. You won't be able to start the form and save it for later.
- You can attach documents to support your request. Please have them ready.
- You'll be able to print a copy for your patient's medical record at the end.